Quick Answer
Kiniksa Pharmaceuticals International, plc reported Stockholders Equity of $567.61 million for the year ending 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +29.5% in Stockholders Equity from 2024 to 2025.
- This data is from Kiniksa Pharmaceuticals International, plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$105.12 million | Q2 2018: $341.80 million | Q3 2018: $318.91 million | Q1 2019: $306.52 million | Q2 2019: $275.20 million | Q3 2019: $251.91 million | Q1 2020: $205.83 million | Q2 2020: $250.42 million | Q3 2020: $358.51 million | Q1 2021: $270.70 million | Q2 2021: $235.79 million | Q3 2021: $214.05 million | Q1 2022: $166.24 million | Q2 2022: $153.49 million | Q3 2022: $384.01 million | Q1 2023: $390.10 million | Q2 2023: $411.66 million | Q3 2023: $405.13 million | Q1 2024: $431.90 million | Q2 2024: $435.10 million | Q3 2024: $437.01 million | Q1 2025: $457.49 million | Q2 2025: $495.01 million | Q3 2025: $535.38 million.
- Over the full 10 years of available data (2016 to 2025), Kiniksa Pharmaceuticals International, plc's Stockholders Equity has grown by 2,305.8%.
- Historical annual values: Fiscal year 2025: $567.61 million | Fiscal year 2024: $438.44 million | Fiscal year 2023: $438.84 million | Fiscal year 2022: $396.15 million | Fiscal year 2021: $185.04 million | Fiscal year 2020: $311.94 million | Fiscal year 2019: $225.42 million | Fiscal year 2018: $279.27 million | Fiscal year 2017: -$89.71 million | Fiscal year 2016: -$25.73 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: